Press Release

Nicox Announces Publication of the Adaptive
Design Period of the NCX 470 Mont Blanc
Phase 3 Trial

• An adaptive design is a useful clinical trial design tool which allowed
identification of the optimal dose of NCX 470 in the Mont Blanc trial, the first
Phase 3 trial of NCX 470

• Both doses of NCX 470 ophthalmic solution tested, 0.065% and 0.1%,
lowered intraocular pressure more than the comparator, latanoprost 0.005%
ophthalmic solution

• The 0.1% NCX 470 concentration was chosen for the remainder of the Mont
Blanc trial and the ongoing Denali trial based on a greater intraocular
pressure reduction compared to the 0.065% concentration and a good safety
profile

November 18, 2024 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international
ophthalmology company, today announced that the design details and results of the
adaptive design period of the NCX 470 Mont Blanc Phase 3 trial evaluating the efficacy
and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension have
been published online in Contemporary Clinical Trials, Volume 147, 2024, 107730 (online
pre-publication https://doi.org/10.1016/j.cct.2024.107730). A portion of this data has
previously been presented as a poster at the 2023 World Glaucoma Congress.

The dose finding Phase 2 trial (Dolomites) tested NCX 470 at several concentrations and
the results suggested that a higher dose than those tested might provide even better
efficacy and safety profile. To test this, concentrations of 0.065% and 0.1% were included
in an adaptive dose selection period of the Phase 3 Mont Blanc trial, which compared the
safety and efficacy of NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution in
adult subjects with open-angle glaucoma or ocular hypertension. At the Week 2 timepoint,
the least-squares mean difference in diurnal intraocular pressure (IOP) compared to
latanoprost were 1.51 mmHg for NCX 470 0.065 % group (p = 0.0308) and 1.71 mmHg
for NCX 470 0.1 % group (p = 0.0123), in favor of NCX 470. The most common side effect
was conjunctival/ocular hyperemia, the frequency and severity of which were similar in
both NCX 470 dosing groups (p > 0.05).

The adaptive dose selection period was used in place of additional dose ranging studies
to select the 0.1% concentration of NCX 470 for the completion of the Mont Blanc clinical
trial as well as the second Phase 3 trial, Denali.

The results of the Mont Blanc trial were announced in October 2022. The second Phase 3
trial of NCX 470, Denali, is ongoing and topline results are expected in the third quarter
of 2025.

www.nicox.com
About Nicox


Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve
ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating
bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox
also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos.
Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially
in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in
multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority
of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part
of the CAC Healthcare index.

For more information www.nicox.com


Analyst coverage


H.C. Wainwright & Co Yi Chen New York, U.S.




The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to
correct or to update the information contained in analyst reports.




Nicox
Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com


Disclaimer


The information contained in this document may be modified without prior notice. This information includes forward-looking
statements. Such forward-looking statements are not guarantees of future performance. These statements are based on
current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and
its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide
updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport
Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website
(www.nicox.com).

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently,
the French language version shall prevail.


Nicox S.A.
Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00




www.nicox.com